KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bristol Myers Squibb (BMY) Invested Capital (2016 - 2026)

Bristol Myers Squibb has reported Invested Capital over the past 18 years, most recently at $64.2 billion for Q1 2026.

  • Quarterly Invested Capital rose 28.94% to $64.2 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $64.2 billion through Mar 2026, up 28.94% year-over-year, with the annual reading at $63.3 billion for FY2025, 1.62% down from the prior year.
  • Invested Capital was $64.2 billion for Q1 2026 at Bristol Myers Squibb, up from $63.3 billion in the prior quarter.
  • Over five years, Invested Capital peaked at $67.3 billion in Q3 2025 and troughed at -$2.6 billion in Q2 2023.
  • The 5-year median for Invested Capital is $49.0 billion (2025), against an average of $43.2 billion.
  • Year-over-year, Invested Capital crashed 140.4% in 2023 and then skyrocketed 2101.61% in 2024.
  • A 5-year view of Invested Capital shows it stood at $37.7 billion in 2022, then increased by 0.82% to $38.0 billion in 2023, then surged by 69.41% to $64.3 billion in 2024, then fell by 1.62% to $63.3 billion in 2025, then increased by 1.43% to $64.2 billion in 2026.
  • Per Business Quant, the three most recent readings for BMY's Invested Capital are $64.2 billion (Q1 2026), $63.3 billion (Q4 2025), and $67.3 billion (Q3 2025).